Vistagen Therapeutics is doubling down on its lead social anxiety candidate, even after the asset failed a phase 3 trial last December. | Vistagen Therapeutics is doubling down on its lead social ...

Three of the top diabetes tech companies put forward new clinical data this week, making the case for their continuous glucose monitors and insulin pumps as they look to expand their reac | Three ...

BridgeBio Pharma has taken another step toward the potential approval of its muscle weakness drug candidate BBP-418, ...

“Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

BD has inked a technological partnership with automation provider Sinteco, aimed at pharmacy robotics. | The goal is to ...

Funding from the National Institutes of Health (NIH) generated $94.15 billion in economic activity and supported 390,863 jobs in 2025, according to a ...

Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its ...

The FDA has resumed review of Capricor Therapeutics’ previously rejected Duchenne muscular dystrophy cell therapy following the biotech’s submission of more clinical data, as well as the newly ...

This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the ...

Bay Area laboratory solutions company Agilent Technologies has agreed to acquire Biocare Medical, a pathology solutions business, in an all-cash transaction valued at $950 million. | Bay Area ...

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...